 |
Tranzyme
Pharma Appoints New Vice President of Business Development &
Licensing
RESEARCH TRIANGLE PARK, N.C. and
SHERBROOKE, Québec (August 10, 2006) -Tranzyme Pharma, a leading
biopharmaceutical company developing novel small molecule
therapeutics for the treatment of gastrointestinal (GI) and
metabolic diseases, announced today the appointment of Eric M.
Nelson, Ph.D., as the Company’s Vice President of Business
Development & Licensing.
Dr. Nelson’s career encompasses 20 years of experience in
business development and licensing for pharmaceutical and
biotechnology companies. Previously, Dr. Nelson served as
Assistant Vice President, Technology Licensing for Wyeth-Ayerst
Laboratories where he was responsible for product licensing in
several therapeutic areas including oncology, anti-inflammatory,
anti-viral and anti-bacterial diseases. While at Wyeth-Ayerst,
Dr. Nelson was also responsible for establishing multiple drug
discovery and development partnerships. Prior to joining
Wyeth-Ayerst, he served as Director, Business Development at
Becton Dickinson & Co. and managed several advanced
drug-delivery R&D alliances. Earlier in his career Dr. Nelson
held appointments with Athena Neurosciences as Manager of
Business Development and with SG Cowan & Co. where he was a
biotechnology securities analyst and biotechnology investment
banker. Immediately prior to joining Tranzyme Pharma, he had a
successful biotechnology consulting practice. Dr. Nelson
received his doctorate degree in oncology and molecular biology
from Johns Hopkins University School of Medicine, and was a
Damon Runyon-Walter Winchell Cancer Research post-doctoral
fellow at Harvard University.
“We are very pleased that Dr. Nelson is joining Tranzyme
Pharma,” said Vipin K. Garg, Ph.D., President & CEO of Tranzyme
Pharma. “He is an accomplished business development executive
with a demonstrated track record in product licensing and
negotiating drug development collaborations. His breadth of
experience will enable him to be very effective in executing our
business strategy and leading our partnership negotiations.”
“I am excited to join Tranzyme Pharma and be part of a creative
and seasoned drug development and management team,” said Dr.
Nelson. “Tranzyme has an outstanding combination of
first-in-class drugs in development for GI and metabolic
diseases, which represent fast-growing markets. Tranzyme is
well-positioned to be successful with the development of its
products internally and to be a strategic partner in the
development and commercialization of innovative therapeutics.”
|
|
|
